MAPT and Alzheimer disease: Since MCI patients were not selected based on AD biomarkers (i.e., presence of beta-amyloid and tau protein in the cerebrospinal fluid)52, this group will likely include a mixture of AD and non-AD cases, hence the milder/diluted effect.